Kaletra and Hepatitis acute - a phase IV clinical study of FDA data

Summary:

Hepatitis acute is reported as a side effect among people who take Kaletra (lopinavir; ritonavir), especially for people who are male, 30-39 old, have been taking the drug for < 1 month also take Truvada, and have Pneumonia.

The phase IV clinical study analyzes which people have Hepatitis acute when taking Kaletra. It is created by eHealthMe based on reports of 22,879 people who have side effects when taking Kaletra from the FDA, and is updated regularly.

What is Kaletra?

Kaletra has active ingredients of lopinavir; ritonavir. It is often used in hiv infection. eHealthMe is studying from 23,070 Kaletra users. Check the latest studies of Kaletra.

What is Hepatitis acute?

Hepatitis acute is found to be associated with 594 drugs and 877 conditions by eHealthMe. Check the latest studies of Hepatitis acute.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

22,879 people reported to have side effects when taking Kaletra.
Among them, 30 people (0.13%) have Hepatitis acute.

Among these 30 people:

How long have people been on Kaletra when they have Hepatitis acute? *

What is the gender of people who have Hepatitis acute when taking Kaletra? *

female: 18.52 %
male: 81.48 %

What is the age of people who have Hepatitis acute when taking Kaletra? *

What are other drugs people take besides Kaletra? *

What are other side effects people have besides Hepatitis acute? *

Progressive Multifocal Leukoencephalopathy (rapidly progressive neuromuscular disease caused by opportunistic infection of brain cells): 5 people, 16.67%
Immune Reconstitution Syndrome (immune recovery syndrome): 5 people, 16.67%
Weakness: 4 people, 13.33%
Speech Impairment (Adult) (inability to speak (adult)): 4 people, 13.33%
Pneumonia: 4 people, 13.33%
Hyporeflexia (a condition of below normal or absent reflexes): 4 people, 13.33%
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 4 people, 13.33%
Speech Disorder: 4 people, 13.33%
Hemiparesis (weakness on one side of the body): 4 people, 13.33%
Dysphemia (stammering or stuttering): 4 people, 13.33%

What are the existing conditions these people have? *

Pneumonia: 4 people, 13.33%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 3 people, 10.00%
Visceral Leishmaniasis (black fever): 1 person, 3.33%
Upper Respiratory Tract Infection: 1 person, 3.33%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 1 person, 3.33%
Pneumonia Viral: 1 person, 3.33%
Frontal Lobe Epilepsy (recurring seizures that arise in the frontal lobes of the brain): 1 person, 3.33%
Acquired Immunodeficiency Syndrome (disease of the human immune system caused by the human immunodeficiency virus (hiv)): 1 person, 3.33%

* Approximation only. Some reports may have incomplete information.

Do you take Kaletra and have Hepatitis acute?

- Check whether Hepatitis acute is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Kaletra:

Kaletra (23,070 reports)

Hepatitis acute treatments and more:

Hepatitis acute (7,695 reports)

Browse all side effects of Kaletra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatitis acute:

Hepatitis acute (594 drugs)

Browse all the conditions that are associated with Hepatitis acute:

Hepatitis acute (877 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on lopinavir; ritonavir (the active ingredients of Kaletra) and Kaletra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.